# Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

Study · id `cardio:ct-nct05326490` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05326490](<https://clinicaltrials.gov/study/NCT05326490>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05326490

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 546 participants.

## Technical summary

Registry record NCT05326490. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-30 (anticipated); primary completion 2024-09-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 546 participants (planned count; ClinicalTrials.gov record NCT05326490, source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)
- Planned start: 2022-05-30 (anticipated) (ClinicalTrials.gov record NCT05326490, source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)
- Primary completion: 2024-09-24 (anticipated) (ClinicalTrials.gov record NCT05326490, source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)
- Completion: 2024-10-31 (anticipated) (ClinicalTrials.gov record NCT05326490, source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05326490, source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05326490-2022-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): PB-201
- Intervention (Drug): PB-201 matched placebo
- Intervention (Drug): Metformin hydrochloride
- Lead sponsor: PegBio Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: PegBio Co., Ltd. (`cardio:org-pegbio-co-ltd`)

## Provenance

Content hash: e83e1df939738b0d1bfb2e21f5f80d012768fcd68c2e5819e6067b7c5c08ebfa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
